Video

Dr. Gupta on safety and sequencing of antibody-drug conjugates in urothelial cancer

Shilpa Gupta, MD, director of Genitourinary Oncology at Cleveland Clinic compares the safety profile of the antibody-drug conjugates (ADCs) sacituzumab govitecan (Trodelvy) and enfortumab vedotin (Padcev). Both ADCs are FDA-approved for the treatment of patients with locally advanced or metastatic urothelial cancer previously treated with chemotherapy and a PD-1/PD-L1 inhibitor.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
© 2025 MJH Life Sciences

All rights reserved.